The ranked assignee list for this corpus is led by a single company holding 3,472 records, well ahead of the next several places, with fifth place at 353 and tenth at 233. The leading ten combined account for 27.4% of all 25,364 records in scope, which means the remaining three-quarters of filings are distributed across a long tail of universities, diagnostics companies, government research bodies and smaller specialty filers. This structure suggests the field is not gated by a small cartel of blocking portfolios, though the single leader's position is substantial in absolute terms.

Filings peaked in 2017 at 794 and have since declined on a complete-year basis, falling from 720 in 2021 to 404 in 2024 — a -44% change over that span. Filings for 2025 and 2026 are lower still in the raw count, but that reflects publication lag of roughly 18 months rather than a real collapse in activity, since recent filings have not all published yet. Anyone using this trend to justify entering or avoiding the space should anchor on the 2021-to-2024 comparison, not the most recent one or two years.

A61K (medicinal preparations) covers 48.5% of the 25,364 records and C07K (peptides and proteins) covers 38.5%, making antibody and reagent chemistry the most heavily claimed layer. G01N (material analysis and testing) and C12N (microorganisms and genetic engineering) follow at 34.1% and 27.5% respectively. Because a single record can carry multiple IPC codes, these shares add up to well over 100%, so they should be read as coverage density per class, not as slices of a single pie.

The IPC composition shows C12P (fermentation and enzymatic synthesis) and C07H (sugars and nucleic acids) each covering roughly a tenth of records, noticeably thinner than the reagent-chemistry classes above them. Combined with the observation that several historically dominant assignees show flat or falling recent-year filings, sub-areas like automated interpretation scoring, control-tissue standardization and protocol harmonization across staining platforms look comparatively under-claimed relative to core antibody and detection chemistry. A freedom-to-operate search focused specifically on those narrower branches, rather than the crowded reagent layer, is the more efficient use of search budget.

US20120295279A1, assigned to Nichirei Biosciences, claims a pretreatment solution for immunohistochemical staining built around an antigen-retrieving agent, specific nonionic surfactants and cyclodextrin or a derivative, formulated so the solution can be reused three or more times, plus a concentrate form for preparing it. It blocks that specific combination of retrieval agent, surfactant class and cyclodextrin component formulated for reuse — it does not block antigen retrieval chemistry generally, nor single-use retrieval solutions, nor formulations built on different surfactant or stabiliser chemistry. Anyone designing around it should look closely at the specific reagent combination and the reusability claim language rather than treating antigen retrieval broadly as blocked.